Insights On Enterprise Solutions

  1. Scaling Cell And Gene Therapy Manufacturing 9/25/2026

    Artificial intelligence is reshaping healthcare. Discover proven strategies for secure, compliant AI adoption, strong data governance, and seamless integration to improve patient outcomes.

  2. Managing Risk Across The Single-Use System Lifecycle 9/24/2026

    Single-use system risk extends from initial design through installation and use. See how lifecycle-wide controls can strengthen contamination prevention and support regulatory readiness.

  3. How Can We Help You Achieve Drug Product Risk Control? 9/24/2026

    Learn how you can strengthen contamination control by applying risk-based principles across the single-use system lifecycle, from design and validation through handling and use.

  4. Single-Use Systems And Drug Product Manufacturing Challenges 9/24/2026

    EU GMP Annex 1 calls for contamination control across the full manufacturing process. Learn why filter integrity testing alone is not enough and how evaluating fluid paths can strengthen quality.

  5. How Does SUS Integrity Change Across The Drug Product Lifecycle? 9/24/2026

    Learn how phase-appropriate risk justification, validation, documentation, and lifecycle controls can strengthen sterility assurance while reducing the potential for rework and delays.

  6. Overview Of Single-Use System Integrity Assurance 9/24/2026

    Single-use system integrity depends on managing risk across the entire life cycle. Explore how materials, packaging, transport, installation, handling, and use influence sterility assurance.

  7. Why Commercial Ready Manufacturing Should Be Considered From Day One 9/24/2026

    Early process decisions can determine whether cell therapies scale efficiently. Explore how automation, robotics, facility design, and manufacturing expertise can reduce batch costs.

  8. Behind The Data: Leveraging Protein And gRNA Engineering 9/24/2026

    See how coordinated optimization of the nickase, deaminase, and guide RNA can increase base editing potency, reduce bystander edits, and improve specificity when an initial candidate falls short.

  9. Behind The Data: Active Learning-Guided Optimization 9/24/2026

    Active learning can accelerate protein engineering by identifying high-performing mutations, revealing interactions between variants, and guiding higher-order designs that improve targeted gene insertion.

  10. Behind The Data: Leveraging Generative AI 9/24/2026

    Combining generative protein design, computational filtering, and experimental feedback produced a de novo deaminase with greater than 20% on-target editing and less than 1% bystander activity.